skip to the content

Clinical Trials

Schizophrenia - Genetic Study

Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients with Schizophrenia

Protocol ID

08-252

Protocol Description

The purpose of this study is to see whether screening for a particular gene can help decide how to best treat patients with the medication, risperidone. This particular gene codes for an enzyme, called “Cytochrome P450 2D6” (CYP2D6), which determines how quickly your body breaks down chemicals such as medications like risperidone.  Some patients respond well to risperidone, but others don’t and they may experience side effects. We don’t really know why this happens. The genetic information will help us to see whether adjusting doses of risperidone can improve clinical care and decrease side effects from the medication. This will ultimately benefit patients with schizophrenia in the future.

Eligibility Criteria

Patients with schizophrenia

Primary Investigator(s)

  • Anil K. Malhotra, MD

Contact Information

Anu Tyagi, MD
(718) 470-8332
atyagi@nshs.edu

Last Update

March 30, 2010
top
  • Share this Page
  • Bookmark this Page
  • Toggle Text Size
  • Print this Page
Search Mental Health:
top
top